DelveInsight’s ‘Uveitis - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Uveitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Uveitis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2016-2027
Uveitis - Disease Understanding and Treatment Algorithm
The DelveInsight Uveitis market report gives the thorough understanding of the Uveitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Uveitis in the US, Europe, and Japan.
The Uveitis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covers the prevalence of both Infectious and Non-Infectious Uveitis (NIU). Prevalence of NIU is further segmented into four types basis of sub-type [Intermediate Uveitis, Pan-Uveitis, Posterior Uveitis, Anterior noninfectious uveitis (aNIU] in 7MM.
According to DelveInsight, the prevalent cases of Uveitis was 706,666 in 2016 in 7 MM, of which 643,721 cases were of Non-Infectious Uveitis (NIU). As per DelveInsight estimation prevalent cases of Uveitis is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. United States account for highest prevalent cases of Uveitis with 392,035 prevalent cases in 2016 followed by France.
Uveitis Drug Chapters
This segment of the Uveitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The market of Uveitis is dominated with corticosteroids, immunosuppressants and biologics. Off-label corticosteroids, immunosuppressive and biologics are also being used for Uveitis. Corticosteroids are used as first line of therapy for treatment of Uveitis. Currently four corticosteroids namely Durezol, Retisert, Ozurdex and Triesence are being used. The first approved monoclonal antibody approved for the treatment of Uveitis was Humira (Adalimumab). This report includes detailed chapters of marketed along with the promising upcoming therapies.
Uveitis Market Outlook
The Uveitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Uveitis market is expected to grow during the forecasted period of 2018-2027 at a CAGR of XX% owing to the launch of nine drugs (presently in Phase III). Uveitis Therapeutics market has seen a global sales of 5.4 billion in 2016. The three best selling drugs were Vimpat (UCB), Lamictal (Glaxosmithkline) and Keppra (UCB) with Vimpat recording highest sales of 895 million in 2016.
Uveitis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Uveitis Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Uveitis Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Uveitis Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Uveitis market
• Organize sales and marketing efforts by identifying the best opportunities for Uveitis market
• To understand the future market competition in the Uveitis market.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook